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ABSTRACT
Blacks have high rates of chronic kidney disease, are overrepresented among the US dialysis patients, have higher parathyroid hormone
levels, but greater survival compared to nonblacks. We hypothesized that mineral and bone disorders (MBDs) have a bearing on survival
advantages of black hemodialysis patients. In 139,328 thrice-weekly treated hemodialysis patients, including 32% blacks, in a large
dialysis organization, where most laboratory values were measured monthly for up to 60 months (July 2001 to June 2006), we examined
differences across races in measures of MBDs and survival predictabilities of these markers and administered the active vitamin D
medication paricalcitol. Across each age increment, blacks had higher serum calcium and parathyroid hormone (PTH) levels and almost
the same serum phosphorus and alkaline phosphatase levels and were more likely to receive injectable active vitamin D in the dialysis
clinic, mostly paricalcitol, at higher doses than nonblacks. Racial differences existed in mortality predictabilities of different ranges of
serum calcium, phosphorus, and PTH but not alkaline phosphatase. Blacks who received the highest dose of paricalcitol (>10mg/week)
had a demonstrable survival advantage over nonblacks (case-mix-adjusted death hazard ratio¼0.87, 95% confidence level 0.83–0.91)
compared with those who received lower doses (<10mg/week) or no active vitamin D. Hence, in black hemodialysis patients,
hyperparathyroidism and hypercalcemia are more prevalent than in nonblacks, whereas hyperphosphatemia or hyperphosphatasemia
are not. Survival advantages of blacks appear restricted to those receiving higher doses of active vitamin D. Examining the effect of MBD
modulation on racial survival disparities of hemodialysis patients is warranted.  2010 American Society for Bone and Mineral Research.
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Introduction
I
n the United States, chronic kidney disease (CKD) is common
and associated with major racial disparities.
(1-3) Approximately
one-third of the 400,000 US dialysis patients are African
Americans, even though they comprise 14% of the US general
population.
(4,5)Theracialdiscrepanciesofdialysisincidencehave
persisted over the past decades. The 2006 incident dialysis
patient rates inthe African-American populationcontinued tobe
3.6 times greater than among non-Hispanic whites.
(4,5) Notwith-
standing the public health implications of the CKD racial
disparities, there are some encouraging facts pertaining to race.
Whereas some two-thirds of all US dialysis patients die within
5 years of initiating dialysis therapy, a death rate currently worse
than most cancers,
(6) African American with end-stage renal
disease (ESRD) have consistently greater survival over the past
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2724two decades than non-Hispanic whites, with an annual
death rate of only 187 per 1000 patient-years at risk versus
207 per 1000 patient-years at risk for non-Hispanic whites.
(4,5)
The causes and consequences of these disparities remain largely
unknown.
The spectrum of kidney bone diseases,
(7,8) also known as the
mineral and bone disorders (MBDs),
(9,10) is not only common and
highly correlated with morbidity and mortality in CKD patients,
but it also is one of the disease conditions with distinct features
and severity across races.
(11–15) In particular, African-American
CKD patients appear to have higher levels of parathyroid
hormone (PTH) and are more likely to receive treatment for
it.
(14,15) A recent epidemiologic study in incident hemodialysis
patients suggested that therapy with activate vitamin D agents
may be a potential explanation for the racial differences in
survival.
(16) It is not clear whether different doses of these
medications have a bearing on survival, in particular, among
prevalent hemodialysis patients, who comprise most of the ESRD
population in the United States.
(4,5)
Understanding these issues is time-sensitive because the so-
called bundling payment for dialysis patient care in the United
States is imminent.
(17–19) The inclusion of MBD-specific medica-
tions such as active vitamin D compounds within a bundled
dialysis payment can have adverse unintended consequences if
the proposed case-mix adjustment does not take into account
race, which may be an important determinant of dosing
requirements and patient survival. We therefore hypothesized
thatAfrican-Americanhemodialysispatientsareamongthemost
susceptiblepopulationsforpotentiallydeleteriousimpactsofthe
currently proposed bundling system, which does not consider
race in adjusting payments. We examined the distribution of
biochemical measures of CKD-MBD and pattern of active vitamin
D treatment across races in a large (over 100,000 subjects) and
contemporary (July 2001 to June 2006) cohort of hemodialysis
patients from a large dialysis organization (DaVita, El Segundo,
CA, USA) with monthly blood to quarterly blood tests and
treatment record over the entire 5 years. We also hypothesized
that African-American hemodialysis patients have distinct
survival associations with surrogates of MBDs and that
higher doses of active vitamin D may explain their survival
advantages.
Methods
Patients
We extracted, refined, and examined data from all individuals
with CKD stage 5 who underwent hemodialysis treatment from
July 2001 to June 2006, that is, for 5 consecutive years, in one of
the outpatient dialysis facilities of a US-based large dialysis
organization (LDO), that is, DaVita (prior to its acquisition of the
former Gambro dialysis facilities). Thestudy wasapproved by the
Institutional Review Committees of both the Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center
and DaVita Clinical Research. Because of the large sample size,
theanonymityofthe patients,andthe nonintrusivenatureofthe
research, the requirement for a written consent form was
exempted.
Clinical and demographic measures
Creation of the cohort has been described previously.
(20–26)
To minimize measurement variability, all repeated measures for
eachpatient during anygivencalendar quarter, that is,over a13-
week or 3-month interval, were averaged, and the quarterly
means in each of the 20 calendar quarters were used in time-
dependent analyses. In addition to quarterly laboratory values,
quarterlyaveragedvaluesforparicalcitol dosegreaterthan0and
posthemodialysis dry weight [to calculate averaged body mass
index (BMI)] also were calculated. Dialysis vintage was defined as
the duration of time between the first day of dialysis treatment
and the first day that the patient entered the cohort. The first
(baseline) study quarter for each patient was the calendar
quarter in which patient’s vintage was more than 45 days during
at least half the time of that quarter.
Laboratory measures
Blood samples were drawn using uniform techniques in all the
DaVita dialysis clinics and were transported to the DaVita
Laboratory in Deland, Florida, typically within 24hours. All
laboratory values were measured by automated and standar-
dized methods in the DaVita Laboratory. Most laboratory values
were measured monthly, including urea nitrogen, creatinine,
albumin, calcium, phosphorus, bicarbonate, and total iron-
binding capacity (TIBC). Serum ferritin and intact PTH were
measured at least quarterly. Hemoglobin was measured at least
monthlyinessentiallyallpatientsandweeklytobiweeklyinmost
patients. Most blood samples were collected before dialysis, with
the exception of the postdialysis serum urea nitrogen (SUN) that
wasobtainedtocalculateureakinetics.TheKt/V(singlepool)was
calculated using urea kinetic modeling (UKM) equations, as
described elsewhere.
(20) Albumin-corrected calcium concentra-
tion was calculated by subtracting 0.8mg/dL for each gram per
deciliter of serum albumin below 4.0g/dL.
(27)
In-center-administered active vitamin D agents
Patients who received any injectable active vitamin D agent
(ie, calcitriol, doxercalciferol, and/or paricalcitol) in the dialysis
facility during each given calendar quarter were identified, and
the administered doses wereextracted. Since over 90% ofDaVita
patients who received any active vitamin D between 2001 and
2006 received paricalcitol (Zemplar, Abbott Laboratories, Abbott
Park, IL, USA), the dose of administered paricalcitol was
calculated in micrograms per week (mg/week) for each calendar
quarter over the entire 5 years of the cohort for every hemodialysis
patient. Patients who received any dose of paricalcitol were
divided into groups of average dose less than 10mg/week and
10mg/week or more. For this study, data on oral medications
including calcimimetics or phosphorus binders were not available.
The calcimimetic cinacalcet became available in the United States
during the last few months of this 5-year cohort.
(28,29) Hence the
cohort is virtually a precalcimimetic cohort.
Statistical and epidemiologic methods
Age-stratified analyses across two mutually exclusive racial
groups were performed to examine the role of race in the
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independent of age. For survival analyses, we employed
proportional hazards regression using quarterly averaged
variables, as described earlier. Patients who were transplanted,
switched to peritoneal dialysis, or left DaVita clinics were
censored at the time of the event. Plots of log[–log(survival rate)]
against log(survival time) were performed to check the
proportionality assumption. For each analysis, two levels of
multivariate adjustment models were examined:
1. Unadjusted (or minimally adjusted) models that included
mortality and censorship data, the predicting variable, and
the entry calendar quarter (Q1 through Q20).
2. Case-mix-adjusted models that included all the preceding
plus age, gender, race/ethnicity (African Americans and
other self-categorized blacks, non-Hispanic whites, Asians,
Hispanics, and others), diabetes mellitus, categories of
dialysisvintage(<6months,6monthsto2years,2to5years,
and 5years ormore), primaryinsurance (Medicare, Medicaid,
private, and others), marital status (married, single, divorced,
widowed, and other or unknown), the standardized
mortality ratio of the dialysis clinic during entry quarter,
residual renal function during the entry quarter, and
Kt/V (single pool) to represents the administered dialysis
dose.
We did not include laboratory measures as additional
adjustors in most regression models. In our view, results from
such excessive adjustments, which we usually refer to as the
malnutrition-inflammation-cachexia syndrome (MICS) controlling,
are likely overadjusted and may introduce new sources of bias
owing to possible inclusion of intermediates in the causal
pathways of the associations under study. On the other hand,
results from the unadjusted models are likely to be profoundly
confounded owing to omission of such inherent confounders as
age and gender. We thus prefer to base inferences on the case-
mix-adjusted models.
Unadjustedandcase-mix-adjustedlogisticregressionanalyses
were used to calculate the odds ratio of receiving the highest
paricalcitol dose (>10mg/week) versus the lowest dose (>0t o
<10mg/week). Most analyses were carried out with SAS Version
9.1 (SAS Institute, Inc., Cary, NC, USA).
Results
The original 5-year (July 2001 to June 2006) national database
of all DaVita hemodialysis patients included 152,058 adults.
After deleting patients who did not maintain at least 45 days of
hemodialysis treatment (9,151 patients from the first 19 calendar
quarters and 3,579 patients from the last quarter), 139,328
hemodialysis patients remained, including 18% incident patients
with a dialysis vintage of less than 6 months (see Supplemental
Table S1 for category comparisons). The cohort included 43,974
African Americans (32%) and 95,354 non-African Americans
(68%). Table 1 shows counts (in percentage) or means (  SD) of
the relevant demographic, clinical, and laboratory variables in
the entry calendar quarter of the patients across eight 10-year
increments of age from younger than 25 years to older than
85 years of age. African Americans younger than 65 years of age
and all non-African-American hemodialysis patients included
more men than women, whereas this ratio reversed among
elderly African Americans. Diabetes mellitus proportion was
lower in younger African Americans than in non-African
Americans, whereas this relationship reversed among older
patients. Delivered Kt/V and serum concentrations of albumin
and TIBC tended to be lower in African Americans across virtually
allagesgroups,whereasserumcreatinineexhibitedtheopposite
trend. Figures 1 through 3 show the distribution of several
relevant MBDmeasures. Amongtheminerals,serumphosphorus
levels appeared essentially the same across the races, whereas
serum calcium concentrations were higher in African Americans
older than 45 years (Fig. 1). Higher PTH levels in African
Americans were persistent regardless of age, whereas serum
alkaline phosphatase levels were not different (Fig. 2). The
proportion of hemodialysis patients who received an active
vitamin D and the average weekly dose among those who
received paricalcitol (comprising 94% of administered active
vitamin D) was higher in African Americans (Fig. 3).
Figures 4and 5showthecomparison ofthe case-mix-adjusted
mortality predictability of the MBD surrogates in all (incident and
prevalent combined) African Americans versus non-African-
American hemodialysis patients.Most selectedcutofflevels were
consistent with the Kidney Disease Outcome Quality Initiative
(KDOQI) recommended target values,
(30) and the reference
group is the target range in African Americans. In African
American but no other patients, a serum calcium concentration
between 9.5 and 10.2mg/dL was associated with the greatest
survival, whereas both hypocalcemia (<8.4mg/dL) and hyper-
calcemia (>10.2mg/dL) were associated with increased death
risk (Fig. 4, left panel). Similarly, increased mortality was observed
with extreme levels of serum phosphorus (Fig. 4, right panel).
As shown in Fig. 5 (left panel), distinct differences across the
racial groups were noticed for certain PTH levels in that in non-
African-American patients, a serum PTH above 300pg/mL was
associated withsubstantial death risk(compared with the KDOQI
recommended range of 150 to 300pg/mL), whereas for both
races, a PTH above 600pg/mL was associated with a substantial
increase in death risk. Serum alkaline phosphatase showed
a rather linear and incremental association with death with
virtually no difference across the races (Fig. 5, right panel). The
same survival analyses but only in 24,509 incident patients
showed slightly different associations (see Supplemental Figs. S1
and S2 for comparison).
We identified 49,674 hemodialysis patients (including 19,918
African Americans) who always received some dose of
paricalcitol (>0mg/week) during each of the 20 calendar
quarters, whereas 18,981 never received any active vitamin D
dose during the cohort. The former group then was divided into
those who received up to an average dose of 10mg/week
(n¼17,347) and those who received higher doses of paricalcitol
(n¼32,327).Logisticregressionwasusedtoexaminefactorsthat
are associated with the probability of receiving the highest
paricalcitol dose (>10mg/week) versus the lowest dose (>0t o
<10mg/week) among those who received this medication. As
shown in Table 2, African Americans had twice the odds of
2726 Journal of Bone and Mineral Research KALANTAR-ZADEH ET AL.Table 1. Comparing Relevant Demographic, Clinical, and Biochemical Characteristics in the Base Calendar Quarter in 139,328
Maintenance Hemodialysis Patients Including 43,974 African Americans (32%) and 95,354 Non-African Americans (68%)
Age groups (years)
<25 25 to <35 35 to <45 45 to <55 55 to <65 65 to <75 75 to <85 >85
AA N¼668 N¼2632 N¼5681 N¼9560 N¼10,479 N¼9053 N¼4908 N¼993
Non-AA N¼1306 N¼3733 N¼7474 N¼13,897 N¼20,421 N¼23,871 N¼20,125 N¼4,527
Age (years) AA 21.5 2.3 30.8 2.7 40.5 2.8 50.3 2.8 60.0 2.8 69.6 2.8 79.0 2.7 88.2 2.6
Non-AA 21.6 2.2 30.6 2.8 40.5 2.8 50.4 2.8 60.1 2.8 70.1 2.8 79.4 2.7 88.0 2.5
Gender (% female) AA 46 42 40 41 49 56 60 64
Non-AA 41 42 38 40 44 45 44 45
Diabetes mellitus (%) AA 9 19 24 38 51 54 48 38
Non-AA 5 21 33 46 55 51 39 26
Ethnicity (% Hispanic) AA <1 <1 <1 <1 <1 <1 <1 <1
Non-AA 36 30 26 26 23 19 12 8
Dialysis vintage (%)
<6 Months AA 12 12 11 12 13 14 19 25
Non-AA 18 15 15 16 17 19 24 29
>5 Years AA 24 33 34 32 27 26 20 13
Non-AA 19 27 26 22 18 16 13 8
Primary insurance (%)
Medicare AA 52 59 58 58 58 75 76 78
Non-AA 45 49 52 50 50 70 73 77
Medicaid AA 16 11 10 8 7 1 <1 <1
Non-AA 16 12 9 8 8 2 <1 <1
Marital status (%)
Married AA 3 17 23 30 35 33 27 17
Non-AA 7 26 37 44 49 49 44 32
Divorced AA <1 269 1 1 85 3
Non-AA <1 489963 2
Single AA 79 61 52 41 29 20 15 13
Non-AA 71 49 36 26 16 10 8 7
Widowed AA <1 <1 <13 92 0 3 3 4 8
Non-AA <1 <1 <12 71 5 2 6 3 9
BMI (kg/m
2) AA 26.0 8.4 28.1 8.6 28.4 8.7 28.5 7.9 28.3 7.6 27.1 6.5 25.0 5.7 23.1 6.0
Non-AA 23.5 6.9 25.5 6.5 26.9 7.6 28.2 7.5 28.2 7.3 26.8 6.4 24.9 5.1 23.5 4.5
Kt/V (dialysis dose) AA 1.4 0.4 1.4 0.4 1.4 0.3 1.4 0.3 1.5 0.3 1.5 0.3 1.5 0.3 1.6 0.3
Non-AA 1.6 0.4 1.5 0.4 1.5 0.4 1.5 0.4 1.5 0.4 1.6 0.4 1.6 0.4 1.6 0.4
Protein catabolic rate AA 0.9 0.3 0.9 0.3 0.9 0.3 0.9 0.3 0.9 0.2 0.9 0.2 0.9 0.2 0.9 0.2
(g/kg/day) Non-AA 1.0 0.26 1.01 0.3 1.0 0.3 1.0 0.3 1.0 0.3 1.0 0.3 0.9 0.3 0.9 0.2
Biochemical measures
Albumin (g/dL) AA 3.8 0.6 3.8 0.6 3.8 0.5 3.7 0.5 3.7 0.5 3.6 0.5 3.6 0.5 3.4 0.5
Non-AA 3.9  0.5 3.9 0.5 3.8 0.5 3.7 0.5 3.7 0.5 3.6 0.5 3.6 0.5 3.5 0.4
Creatinine (mg/dL) AA 11.8 4.3 11.9 4.3 11.2 3.9 10.1 3.5 8.9 3.1 8.1 2.8 7.3 2.5 6.4 2.3
Non-AA 10.8 3.5 10.3 3.8 9.3 3.5 8.2 3.1 7.3 2.8 6.7 2.5 6.1 2.3 5.6 2.0
TIBC (mg/dL) AA 195 41 198 42 207 44 211 46 204 46 196 43 188 43 179 44
Non-AA 208 43 211 44 212 46 215 48 214 47 210 47 205 46 200 46
Phosphorus (mg/dL) AA 6.6 1.7 6.3 1.7 6.1 1.6 5.8 1.5 5.5 1.4 5.1 1.3 4.9 1.3 4.6 1.3
Non-AA 6.7 1.8 6.5 1.8 6.3 1.7 6.0 1.6 5.6 1.5 5.3 1.4 5.0 1.3 4.8 1.2
Calcium (mg/dL) AA 9.2 0.9 9.2 0.9 9.2 0.8 9.3 0.8 9.3 0.7 9.4 0.7 9.3 0.7 9.2 0.7
Non-AA 9.2 0.9 9.2 0.8 9.2 0.8 9.2 0.8 9.2 0.7 9.2 0.7 9.2 0.7 9.1 0.7
Intact PTH (ng/mL) AA 671 604 611 563 576 518 514 477 449 408 400 347 372 331 342 301
Non-AA 575 588 501 497 438 416 375 357 326 306 292 265 268 235 265 213
Alkaline AA 144 121 130 98 137 115 141 118 132 96 121 77 116  72 110 75
phosphatase (U/L)
(Continued)
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however, that because the outcome (high dose) is so common,
this doubling of the odds is much larger than the increase in
probability of a high dose. Higher serum levels of calcium,
phosphorus, PTH, or alkaline phosphatase levels were associated
with the higher paricalcitol dose.
Figure 6 shows hazard ratios for death of African Americans
compared with non-African Americans across low and high
doses of paricalcitol. In the no active vitamin D group and the
low-paricalcitol-dose group, African Americans did not show any
survival advantages compared with others, whereas among
those who received a high paricalcitol dose, 12% greater survival
was noticed (Fig. 6). This association was consistent among
incident patients (data no shown) and across most age groups
(see Supplemental Fig. S3). The association of survival superiority
of African Americans and higher paricalcitol dose appeared
independent of additional adjustments in sensitivity analyses
(see Supplemental Fig. S4 for sensitivity analyses).
Discussion
Among 139,328 thrice-weekly-treated hemodialysis patients,
including 32% African Americans, in a single large dialysis
organization, where most laboratory values were measured
monthly up to 60 months (July 2001 to June 2006), we found
that African-American hemodialysis patients had higher serum
calcium and PTH levels than—but similar phosphorus and
alkaline phosphatase levels as—other races, implying that the
chemical hyperparathyroidism in African Americans may not
cause a more severe bone disease. They also were more likely to
receive injectable active vitamin D compounds, and when they
did, they tended to receive higher doses of these medications.
Survival analyses comparing the two races showed subtle but
distinct differences in mortality predictabilities of different
ranges of serum calcium, phosphorus, and PTH but not alkaline
phosphatase. African Americans who received the highest
paricalcitol dose ( 10mg/week) had a demonstrable survival
advantage compared with African Americans who received no
active vitamin D or only low doses of paricalcitol (<10mg/week).
These findings may have important implications for the
management of dialysis patients of different races, especially
since guidelines and conditions for pay for performance might
not devote adequate attention to the role of race in the
management of CKD-MBD in hemodialysis patients. ESRD
incidence and prevalence have been rising in the United States
and in most countries around the world.
(31) There are currently
approximately 400,000 Americans who undergo maintenance
dialysis treatment to survive, and one-third of them are African
Americans. Racial discrepancies in CKD have persisted over
the past 20 years.
(3) The annual ESRD incidence for African
Americans in 2006 reached 1010 per million, which is 3.6 times
greater than non-Hispanic whites.
(31) Prevalence of ESRD
continues to be highest for African Americans, at 5004 per
million population in 2006, compared with 1194 among
whites.
(31) In many dialysis clinics in inner-city areas, over half
to two-thirds of dialysis patients are African American.
(31) The
medianageoftheprevalentESRDpopulation,whichis58.8years,
ranges from 56.9 years in the African Americans to 60.0 years
among whites.
(6,31) As shown in Table 1, in our study across
virtually all age groups, approximately one-third of the dialysis
Table 1. (Continued)
Age groups (years)
<25 25 to <35 35 to <45 45 to <55 55 to <65 65 to <75 75 to <85 >85
AA N¼668 N¼2632 N¼5681 N¼9560 N¼10,479 N¼9053 N¼4908 N¼993
Non-AA N¼1306 N¼3733 N¼7474 N¼13,897 N¼20,421 N¼23,871 N¼20,125 N¼4,527
Non-AA 141 164 132 100 136 107 138 110 133 88 122 81 114 66 113 59
Ferritin (ng/mL) AA 477 486 539 654 529 561 538 507 576 547 586 518 598 555 584 488
Non-AA 399 455 434 455 455 452 492 502 501 479 521 486 512 476 491 428
Hemoglobin (g/dL) AA 11.5 1.8 11.6 1.6 11.7 1.5 11.8 1.5 11.8 1.4 11.8 1.4 11.9 1.4 11.8 1.4
Non-AA 11.9 1.5 11.9 1.5 11.9 1.5 11.9 1.4 12.0 1.4 12.0 1.3 12.0 1.3 12.1 1.3
White blood count
(  10
3/L)
AA 7.1 2.6 6.8 2.4 6.8 2.3 6.9 2.3 7.0 2.4 6.9 2.4 6.9 2.7 6.9 2.6
Non-AA 7.2 2.4 7.5 2.4 7.6 2.6 7.7 2.5 7.7 2.7 7.7 2.6 7.8 2.9 7.9 3.3
Lymphocyte AA 26 10 25 92 4  82 3  82 3  82 2  82 2  82 1  8
Non-AA 24 92 3  82 0  72 0  71 9  71 8  71 8  71 8  7
(% of total white blood cell count)
% active vitamin D
a AA 62 63 65 67 66 69 67 67
Non-AA 46 49 51 51 51 51 50 53
Paricalcitol dose
b
(mg/ week)
AA 20.4 12.3 20.1 11.1 20.0 10.9 18.8 10.1 17.6 9.5 16.0 8.9 14.7 8.4 13.6 7.7
Non-AA 15.7 10.5 15.3 9.2 15.1 9.2 14.2 9.2 13.2 8.2 12.0 7.4 10.9 6.5 10.3 6.0
Note: Values are in percentage or mean SD, as appropriate.
aActive vitamin D compounds included paricalcitol, calcitriol, and doxercalciferol.
bAmong those who had received any paricalcitol dose during each of the 20 calendar quarters.
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Fig. 3. PatternofactivevitaminDadministrationin theexaminedcalendarquartersacrosseight10-yearageincrementsin139,328hemodialysispatients
from July 2001 to June 2001. (Left panel) Proportion of hemodialysis patients who received any dose of an active vitamin D compound (paricalcitol 58%,
calcitriol 2%, doxercalciferol <1%, and no active vitamin D 38%) in 43,974 African-American and 95,354 non-African-American hemodialysis patients.
(Right panel) The 3-month average administered paricalcitol dose (mean SD) among 49,674 hemodialysis patients (including 19,918 African Americans)
who received any dose of paricalcitol during the calendar quarter.
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Fig. 1. Comparing 3-month average serum calcium (left panel) and phosphorus (right panel) concentrations in the base calendar quarter across eight 10-
year age increments in 139,328 hemodialysis patients including 43,974 African Americans (32%) and 95,354 non-African Americans (68%) from July 2001
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RACE AND SHPT Journal of Bone and Mineral Research 2729patients were African Americans compared with 14% of the US
general population.
(31)
Among diverse CKD complications, MBDs are more prevalent
in African Americans, in whom PTH levels are elevated in
comparison with other races.
(11–15) In a recent descriptive cohort
study in 1860 predialysis CKD patients including 227 African
Americans, the latter patients had lower levels of 25-hydro-
xyvitamin D [25(OH)D, calcidiol], almost the same levels of 1,25-
dihydroxyvitamin D3 [1.25(OH)2D3, calcitriol] but higher levels of
calcium, phosphorus, and PTH, and were more likely to have
hyperphosphatemia than other races.
(32) In our prevalent
hemodialysis cohort we found that serum calcium and PTH
levels were higher in African Americans, but serum phosphorus
and alkaline phosphatase levels were not (Figs. 1 and 2), even
though these patients were more likely to have received active
vitamin D and at even higher doses, which should increase
gastrointestinal phosphorus absorption. These unique features
of CKD-MBD in the African-American race suggest that more
complicated mechanisms exist that deserve further investiga-
tions based on novel hypotheses.
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Americans have lower levels of circulating calcidiol, there is
no increased musculoskeletal disease that would be expected
owing to such a deficiency, and African Americans indeed
have lower rates of osteoporotic fractures.
(33) There are several
theories about the protective mechanisms of vitamin D
deficiency. A potential adaptive response may involve compen-
satory increases in functionality of circulating calcitriol, that is,
active vitamin D, that depends on 1a-hydroxylase in the kidneys
and which is tightly regulated by circulating levels of calcium,
phosphorus, and PTH. With moderately low levels of 25(OH)2D3,
there is upregulation of PTH with subsequently increased renal
1,25(OH)2D3 production.
(34)
There is also evidence that in African Americans, intestinal
vitaminDreceptorsarelesssusceptibletothemineralabsorptive
actions of 1,25(OH)2D3. The foregoing combination may lead to
the beneficial bone effects of increased 1,25(OH)2D3 without
hyperphosphatemia or only mild hypercalcemia in African
Americans, as we have observed in our national database.
(34)
Hence it is possible that active vitamin D supplementation is
uniquely crucial in African-American CKD patients, in whom the
foregoing protective effects wane with progressively less renal
1a-hydroxylation.
Although dialysis therapy is expected to be lifesaving, ironically,
approximately 1 of every 5 American dialysis patients dies each
year, that is a 5-yearsurvivalofonly approximately 35%,
(5,35) which
isworsethanmostcancersinthetwenty-firstcentury.
(5,35,36) Atany
given age, group dialysis mortality is 10 to 100 times higher than
thatof nondialysisMedicare patients.
(4,31,37) Almost half the deaths
areattributedtocardiovasculardisease.
(35,38,39)Yet,forreasonsthat
are as yet unknown, African-American dialysis patients have
greater survival than their non-Hispanic white counterparts, a
finding that has persisted over the past two decades.
(4,5) The
greater survival of African Americans is robust and consistent not
Table 2. Odds Ratio of Receiving the Highest Paricalcitol Dose ( 10mg/Week, n¼32,327) Versus the Lowest Paricalcitol Dose (>0t o
<10mg/Week, n¼17,347) in 49,674 Hemodialysis Patients Who Received Any Dose of Paricalcitol During All 20 Calendar Quarters of the
Cohort (July 2001 to June 2006)
Unadjusted Case-mix adjusted
Age (each 10-year increase) 0.8 (0.7–0.8)
  0.8 (0.8–0.9)
 
Gender (women versus men) 1.0 (1.0–1.1) 1.0 (1.0–1.1)
Diabetes mellitus (versus no diabetes) 0.9 (0.8–0.9)
  0.9 (0.9–1.0)
 
Race/ethnicity
Non-Hispanic whites (reference) 1 1
African Americans 2.6 (2.5–2.7)
  2.1 (2.0–2.2)
 
Hispanics 1.1 (1.0–1.1)
  0.9 (0.8–1.0)
 
Asians 0.7 (0.7–0.8)
  0.6 (0.6–0.7)
 
Dialysis treatment vintage time
<6 Months (reference) 1 1
6–24 Months 1.1 (1.1–1.2)
  1.0 (1.0–1.1)
2–5 Years 1.7 (1.6–1.8)
  1.5 (1.4–1.6)
 
>5 Years 2.6 (2.4–2.7)
  2.1 (1.9–2.3)
 
Primary insurance
Medicare (reference) 1 1
Medicaid 1.3 (1.1–1.4)
  0.9 (0.9–1.0)
 
Private insurance 1.1 (1.0–1.1) 0.9 (0.9–1.1)
Kt/V (each 0.1-unit increase) 1.0 (0.9–1.0)
  1.0 (0.9–1.0)
 
nPCR (nPNA) (each 0.1 g/kg/day increase) 1.0 (1.0–1.1)
  1.0 (1.0–1.1)
 
BMI (each 1 kg/m
2 increase) 1.0 (1.0–1.1)
  1.0 (1.0–1.1)
 
Biochemical measures
Albumin (each 0.1 g/dL increase) 1.1 (1.0–1.1)
  1.0 (1.0–1.1)
 
Creatinine (each 1 mg/dL increase) 1.2 (1.1–1.2)
  1.1 (1.0–1.1)
 
TIBC (each 10 mg/dL increase) 1.0 (1.0–1.1)
  1.0 (1.0–1.1)
 
Phosphorus (each 1 mg/dL increase) 1.4 (1.3–1.4)
  1.3 (1.3–1.4)
 
Calcium
a (each 1 mg/dL increase) 1.4 (1.3–1.4)
  1.4 (1.3–1.4)
 
Ferritin (each 100 ng/mL increase) 1.0 (1.0–1.1)
  1.0 (0.9–1.0)
Hemoglobin (each 1 g/dL increase) 1.0 (0.9–1.0)
  1.0 (0.9–1.0)
 
WBC (each 10
3/mL increase) 0.9 (0.9–1.0)
  1.0 (0.9–1.0)
 
Lymphocyte (each 1% of total WBC increase) 1.0 (1.0–1.1)
  1.0 (1.0–1.1)
 
Intact PTH (each 100 pg/mL increase) 1.4 (1.3–1.4)
  1.3 (1.3–1.4)
 
Alkaline phosphatase (each 10 U/L increase) 1.0 (1.0–1.1)
  1.1 (1.0–1.1)
 
nPCR, normalized protein catabolic rate; nPNA, normalized protein nitrogen appearance.
aSerum calcium is adjusted for serum albumin.
 p<.001.
RACE AND SHPT Journal of Bone and Mineral Research 2731only irrespective of demographic or residency status but also
independent of the type of dialysis (hemodialysis [HD] versus
peritoneal dialysis), dialysis dose, or other factors related to dialysis
treatment or technique. The racial disparities persist for cause-
specific mortality: For instance, African-American dialysis patients
are17%lesslikelytodieofcardiovasculardiseasethanwhites.
(31,37)
Recent observational studies have suggested a rather
persistent mortality predictability of high serum calcium and
phosphorus levels in CKD patients, in particular, in maintenance
dialysis patients.
(40–42) These associations are often attributed to
increased cardiovascular risk as a results of enhanced calcifica-
tion of the vessels, including coronary arteries, on calcium and
phosphorusloadaccordingtosome
(43,44)butnotall
(45,46)studies.
We found that in ranges around the KDOQI-recommended
target for calcium and phosphorus, African-American hemodia-
lysis patients had slight greater survival chances than other races
(Fig. 4). Additional subtle differences were noticed, including the
observation that a borderline high serum calcium concentration
of 9.5 to 10.2mg/dL was associated with the greatest survival in
African Americans but not other hemodialysis patients (Fig. 4),
although in incident patients, some of these associations
appeared different. Moderately high PTH levels exhibited slightly
different mortality predictabilities in moderately high ranges,
whereas virtually no difference was observed for alkaline
phosphatase (Fig. 5). Alkaline phosphatase has been shown
both in previous studies
(23,46,47) and in this study to be the only
BMD marker with a strictly linear and incremental mortality
predictability, whereas other MBD surrogates exhibit rather U-
shaped associations (Figs. 4 and 5).
A recent study in 9303 incident hemodialysis patients
including 3214 African Americans by Wolf and colleagues
(16)
suggested that therapy with activate vitamin D may be a
potential explanation for racial survival differences in incident
hemodialysis patients, especially since African-American CKD
patients, by virtue of having higher PTH levels, are more likely to
receive injectable vitamin D compounds in dialysis clinics. In our
study we found that low paricalcitol doses (<10mg/week) were
not associated with survival differences across races, whereas
higher doses(>10mg/week)wereso(Fig.6). Asdiscussedearlier,
there may be inherent constellations of PTH and active vitamin D
that are crucial to the musculoskeletal and cardiovascular
physiologies of African Americans in general and the subgroup
with CKD in particular.
A limitation of our study is that we did not have access to the
intake and types of phosphorus binders or other oral
medications related to MBDs, such as oral nutritional vitamin
D. However, it is highly unlikely that US dialysis patients,
especially during the 2001–2006 era, received nutritional
vitamin D,
(48) even though this practice pattern may be more
common in other countries. Although it could be argued that
minerals, PTH, and even alkaline phosphatase are significantly
affected by calcimimetics, a new group of medications,
(29) our
cohort belonged to the precalcimimetic era. We also lacked
detailed and updated data on comorbid states and explicit
laboratory markers of inflammation such as C-reactive protein.
However, as discussed earlier, we believe that adjustment for the
MICS may be inappropriate and introduce new sources of errors
and bias, especially if survival benefits of higher doses of active
vitamin D are exerted though modulating the MICS-related
pathways, among others. Hence we think that the case-mix-
adjusted models are the most appropriate ones.
Thestrengths ofourstudy include (1)itscontemporary nature,
sinceallpatientdatawereobtainedfromthetwenty-firstcentury
(2001–2006), (2) its uniform laboratory measurements, with all
laboratory data obtained from one single facility, (3) its large
sample size, (4) its time-averaged Kt/V and laboratory data, with
most values representing means of up to 3-monthly measure-
ments, and (5) its examination of a 5-year cohort rather than
shorter (1-to 3-year) periods of time used in previous
studies.
(49,50)
Conclusions
Among 139,328 thrice-weekly-treated hemodialysis patients,
including 32% African Americans, in a single large dialysis
organization, where most laboratory values were measured
monthly for up to 60 months (July 2001 to June 2006), we
found that African Americans had higher serum calcium and PTH
levels but similar concentrations of phosphorus and alkaline
phosphatase and were more likely to receive injectable active
vitamin D medications and at higher doses than their non-
African-American counterparts. Subtle but distinct differences in
mortality predictabilities of different ranges of serum calcium,
phosphorus, and PTH but not alkaline phosphatase were
observed across the two groups and among incident versus
prevalent patients. African Americans who had received higher
doses of paricalcitol (>10mg/week) had a demonstrable survival
advantage compared with African Americans who had received
no active vitamin D or lower doses. Given both current KDOQI
guidelines and upcoming conditions for pay for performance
under the imminent bundling system that may lead to changes
in the management patterns of CKD-MBD among US dialysis
patients, our findings may have important implications and, if
verified, may suggest more attention to the inclusion of race as
an independent adjustor in the bundling equations.
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